HIMS expands its Weight Loss Program to the United Kingdom, bringing personalized, doctor-designed care and broader access to obesity treatments.

Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store.

HIMS expands its tech-driven care with new diagnostics, hormonal treatments, and a Canada launch via Livewell.

Hims and Hers (HIMS, Financials) is taking another step in its push into weight-management care, bringing its popular program to customers in the U.K. For those w

LONDON--(BUSINESS WIRE)--Hims & Hers is deepening its commitment to the UK by bringing access to its comprehensive Weight Loss Programme to customers. This expansion includes the official introduction of the Hers platform, helping eligible women across the UK receive access to this holistic weight management care. Sixty four percent of UK adults are overweight or living with obesity, yet access to GLP-1 treatment plans remains challenging on the NHS, and via the private sector due to surgin.

HIMS expands into Canada and Europe while facing regulatory hurdles and execution risks in weight-loss care.

Investors interested in Medical Info Systems stocks are likely familiar with Omnicell (OMCL) and Hims & Hers Health, Inc. (HIMS). But which of these two stocks presents investors with the better value opportunity right now?

Hims & Hers Health has sold off ~40% GLP-1 turbulence, but the core growth story remains intact. The company is building a moat through personalized medicine, vertical integration, and diversification beyond GLP-1s, reducing regulatory and competitive risks. By assuming very achievable growth rates, the company seems to be undervalued by up to 102%.

Hims and Hers Health (NYSE: HIMS - Get Free Report) and HeartSciences (NASDAQ: HSCS - Get Free Report) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, analyst recommendations, risk, dividends, earnings, institutional ownership and profitability. Insider and Institutional Ownership 63.5% of Hims